Neuropathic Pain Treatment Market to Reach $19.2 Billion by 2035

Neuropathic pain treatment market was valued at $10.9 billion in 2025 and is projected to reach $19.2 billion by 2035, growing at a CAGR of 5.8% during the forecast period (2026–2035). The increasing global burden of chronic diseases, particularly diabetes and cancer, is significantly driving demand for neuropathic pain therapies. Neuropathic pain arises from nerve damage and is often chronic and difficult to treat, requiring long-term therapeutic management through pharmacological and non-pharmacological approaches. The growing aging population, coupled with the rising prevalence of nerve-related disorders, is further accelerating the demand for effective treatment solutions.

Browse the full report description of “Neuropathic Pain Treatment Market Size, Share & Trends Analysis Report, By Drug Class (Antidepressants, Anticonvulsants, Opioids, Topical Agents, Others), By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), By Indication (Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Chemotherapy-Induced Peripheral Neuropathy, Trigeminal Neuralgia, Spinal Cord Injury Pain, Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/neuropathic-pain-treatment-market

Pharmacological treatments remain the dominant segment, driven by widespread use of antidepressants and anticonvulsants as first-line therapies. However, non-pharmacological treatments such as neuromodulation and physical therapy are gaining traction as complementary approaches. Increasing awareness, improved diagnosis rates, and expansion of healthcare access are reinforcing long-term market growth across developed and emerging regions.

Rising Diabetes Prevalence Driving Neuropathic Pain Cases

Globally, the increasing prevalence of diabetes is a major macro driver contributing to the growth of the neuropathic pain treatment market. According to the World Health Organization, approximately 422 million people globally were living with diabetes as of recent estimates, with a significant proportion at risk of developing diabetic peripheral neuropathy. Additionally, data from the

In the United States, the This rising patient pool is directly increasing the demand for neuropathic pain medications, particularly anticonvulsants and antidepressants, thereby supporting sustained market expansion.

The growing burden of chemotherapy-induced peripheral neuropathy and postherpetic neuralgia is also contributing to market growth, as cancer treatments and aging populations increase globally. These conditions require long-term pain management, further driving adoption of advanced therapeutic options.

Strategic Developments Strengthening Market Expansion

The neuropathic pain treatment market is characterized by continuous innovation, drug development, and strategic collaborations among key pharmaceutical companies. Leading players such as Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Eli Lilly and Company are actively investing in research and development to introduce more effective and targeted therapies.

• In March 2026, Hikma Pharmaceuticals strengthened its position in the neuropathic pain treatment market by launching the first authorised generic version of extended-release tapentadol (Nucynta® ER) in the United States. This development follows its earlier 2026 launch of the immediate-release version, demonstrating a strategic expansion of its pain management portfolio. The introduction of this generic alternative is expected to improve patient access to cost-effective treatments for severe and diabetic peripheral neuropathic pain.
• In August 2024, the . These regulatory initiatives are encouraging pharmaceutical companies to invest in novel drug formulations and combination therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o Drug Class
  o Treatment Type
  o Indication
  o Competitive Landscape – Pfizer Inc., Johnson & Johnson (Janssen Pharmaceuticals), Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan), Eli Lilly and Company, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Neuropathic Pain Treatment Market Report Segment

By Drug Class

• Antidepressants
• Anticonvulsants
• Opioids
• Topical Agents
• Others

By Treatment Type

• Pharmacological Treatment
• Non-Pharmacological Treatment

By Indication

• Diabetic Peripheral Neuropathy
• Postherpetic Neuralgia
• Chemotherapy-Induced Peripheral Neuropathy
• Trigeminal Neuralgia
• Spinal Cord Injury Pain
• Others

Global Neuropathic Pain Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/neuropathic-pain-treatment-market